Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use

International Journal of Drug Policy

Volumn 24, Issue 6, 2013, Pages 511-516

  Walsh, Zach ^a   Callaway, Robert ^b   Belle Isle, Lynne ^c,d   Capler, Rielle ^e   Kay, Robert ^f   Lucas, Philippe ^d   Holtzman, Susan ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b 1814B Edgehill Court ^*  (Canada)

^c CANADIAN AIDS SOCIETY   (Canada)

^d UNIVERSITY OF VICTORIA   (Canada)

^e Canadian Association of Medical Cannabis Dispensaries   (Canada)

^f Green Cannapy Research and Development   (Canada)

Author keywords

Access to cannabis; Cannabis; Medical marijuana

Indexed keywords

MEDICAL CANNABIS;

ADULT; ANXIETY DISORDER; ARTHRITIS; ARTICLE; BLADDER DYSFUNCTION; CANADA; CANNABIS USE; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; DRUG LEGISLATION; DRUG MONITORING; DRUG SAFETY; FEMALE; HEALTH CARE ACCESS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL HISTORY; MIDDLE AGED; PAIN; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RISK BENEFIT ANALYSIS; SEIZURE; SLEEP DISORDER; TREATMENT OUTCOME; URBAN RURAL DIFFERENCE; ADOLESCENT; ATTITUDE TO HEALTH; COMPARATIVE STUDY; CRIME; DRUG CONTROL; HEALTH BEHAVIOR; HEALTH CARE DELIVERY; HEALTH CARE POLICY; LEGISLATION AND JURISPRUDENCE; MEDICINAL PLANT; PATIENT; PATIENT SATISFACTION; PHYTOTHERAPY; PSYCHOLOGY; SUPPLY AND DISTRIBUTION; YOUNG ADULT;

ADOLESCENT; ADULT; CANADA; CRIME; CROSS-SECTIONAL STUDIES; DRUG AND NARCOTIC CONTROL; FEMALE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MEDICAL MARIJUANA; MIDDLE AGED; PATIENT SATISFACTION; PATIENTS; PHYTOTHERAPY; PLANTS, MEDICINAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890435285     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2013.08.010     Document Type: Article

References (31)

1. Abel E.L. Marijuana: The first twelve thousand years 1980, Plenum Press, New York.
2. Adlaf E.M., Begin P., Sawka E. Canadian Addiction Survey (CAS): A national survey of Canadian's use of alcohol and other drugs: Prevalence of use and related harms: Detailed report 2005, Canadian Centre on Substance Use, Ottawa.
3. Belle-Isle L., Hathaway A. Barriers to access to medical cannabis for Canadians living with HIV/AIDS. AIDS Care 2007, 19:500-506. 10.1080/09540120701207833.
4. Bottorf J.L., Bissell L.J., Balneaves L.G., Oliffe J.L., Capler N.R., Buxton J. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study. Harm Reduction Journal 2013, 10:1-10. 10.1186/1477-7517-10-2.
5. Braitstein P., Kendall T., Chan K., Wood E., Montaner J.S., O'Shaughnessy M.V., Hogg R.S. Mary-Jane and her patients: Sociodemographic and clinical characteristics of HIV-positive individuals using medical marijuana and antiretroviral agents. AIDS 2001, 15:532-533.
6. Brown C., Conner K., Copeland V.C., Grote N., Beach S., Battista D., Reynolds C.F. Depression stigma, race, and treatment seeking behavior and attitudes. Journal of Community Psychology 2010, 38:350-368.
7. Canadian Medical Association Our members' views on medicinal marijuana 2012, Retrived from http://www.cma.ca/advocacy/epanel-medicinal-marijuana.
8. Clark A.J., Ware M.A., Yzer E., Murray T.J., Lynch M.E. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004, 62:2098-2100.
9. Earleywine M. Understanding marijuana: A new look at the scientific evidence 2005, Oxford University Press, New York.
10. Eysenbach G. Improving the quality of web surveys: The checklist for reporting the results of internet e-surveys. Journal of Medical Internet Research 2004, 3:e34. 10.2196/jmir.6.3.e34.
11. Grotenherman F., Schnelle M. Survey on the medical use of cannabis and THC in Germany. Journal of Cannabis Therapeutics 2003, 3(2):17-40. 10.1300/J175v03n02_03.
12. Harris D., Jones R.T., Shank R., Nath R., Fernandez E., Goldstein K., Mendelson J. Self-reported marijuana effects and characteristics of 100 San Francisco medical marijuana club members. Journal of Addictive Diseases 2000, 19(3):89-103. 10.1300/J069v19n03_07.
13. Hazekamp A., Heerdink E. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. European Journal of Clinical Pharmacology 2013, 69:1575-1580. 10.1007/s00228-013-1503-y.
14. Hazekamp A., Mueller-Vahl K., Ware M., et al. The medicinal use of cannabis and cannabinoids; an international cross-sectional survey on methods of intake. Journal of Psychoactive Drugs 2013, in press.
15. Health Canada Canadian Alcohol and Drug Use Monitoring Survey (CADUMS) 2011, Retrieved from http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2011/summary-sommaire-eng.php.
16. Health Canada Harper government announces new marihuana for medical purposes regulatios: Changes improve public safety maintain patient access 2012 (December 26), Retrieved from http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2012/2012-193-eng.php.
17. Health Canada Marihuana medical access program statistics 2012, Retrieved from: http://www.hc-sc.gc.ca/dhp-mps/marihuana/stat/index-eng.php#a1.
18. Holland J. The pot book: A complete guide to cannabis: Its role in medicine, politics, science, and culture 2010, Park Street Press, Toronto.
19. Iverson L.L. The science of marijuana 2008, Oxford University Press., Oxford, UK. 2nd ed.
20. Joy J., Watson S., Benson J. Marijuana and medicine 2003, National Academy Press, Institute of Medicine.
21. Kassam A., Patten S.B. Major depression, fibromyalgia and labour force participation: A population-based cross-sectional study. BMC Musculoskeletal Disorders 2006, 7:4. 10.1186/1471-2474-7-4.
22. Lucas P. Regulating compassion: An overview of Canada's federal medical cannabis policy and practice. Harm Reduction Journal 2008, 5:5. 10.1186/1477-7517-5-5.
23. Lucas P. It can't hurt to ask; A patient-centered quality of service assessment of Health Canada's medical cannabis policy and program. Harm Reduction Journal 2012, 9(2). 10.1186/1477-7517-9-2.
24. Nakagawa S. A farewell to Bonferroni: The problems of low statistical power and publication bias. Behavioral Ecology 2004, 15(6):1044-1045.
25. Reiman A. Medical cannabis patients: Patient profiles and health care utilization patterns. Complementary Health Practice Review 2007, 12:31-50. 10.1177/1533210107301834.
26. Reinarman C., Cohen P.D.A., Kaal H.L. The limited relevance of drug policy: Cannabis in Amsterdam and in San Francisco. American Journal of Public Health 2004, 94:836-842. 10.2105/AJPH.94.5.836.
27. Reinarman C., Nunberg H., Lanthier F., Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. Journal of Psychoactive Drugs 2011, 43:128-135. 10.1080/02791072.2011.587700.
28. Statistics Canada 2006 census of population 2006, Retrieved from http://www12.statcan.gc.ca/census-recensement/2006/index-eng.cfm.
29. Swift W., Gates P., Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduction Journal 2005, 2:18-27. 10.1186/1477-7517-2-18.
30. Ware M.A., Adams H., Guy G.W. The medicinal use of cannabis in the UK: Results of a nationwide survey. International Journal of Clinical Practice 2005, 59:291-295. 10.1111/j. 1368-5031.2005.00271. x.
31. Ware M.A., Rueda S., Singer J., Kilby D. Cannabis use by persons living with HIV/AIDS: Patterns and prevalence of use. Journal of Cannabis Therapeutics 2003, 3(2):3-15. 10.1300/J175v03n02_02.